Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Lisa D Earnhardt. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Lisa D Earnhardt har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:ABT / Abbott Laboratories | EVP AND GROUP PRESIDENT | 71 928 |
US:XENT / Intersect ENT Inc | Director | 48 333 |
US:NVRO / Nevro Corp. | Director | 5 303 |
US:KNSY / Kensey Nash Corp | Director | 0 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Lisa D Earnhardt. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Lisa D Earnhardt som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-07 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 71 928 | −0,28 | 136,64 | −27 329 | 9 828 602 | |
2025-03-07 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 200 | 72 128 | 0,28 | 80,98 | 16 196 | 5 840 925 | |
2025-03-07 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −91 167 | 71 928 | −55,90 | 133,82 | −12 199 968 | 9 625 405 | |
2025-03-07 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 91 167 | 163 095 | 126,75 | 80,98 | 7 382 704 | 13 207 433 | |
2025-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −8 322 | 71 928 | −10,37 | 135,87 | −1 130 710 | 9 772 857 | |
2025-02-27 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 18 788 | 80 250 | 30,57 | ||||
2024-05-08 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −22 852 | 61 462 | −27,10 | 106,25 | −2 428 119 | 6 530 589 | |
2024-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −694 | 84 314 | −0,82 | 118,50 | −82 239 | 9 991 209 | |
2024-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −7 669 | 85 008 | −8,27 | 120,05 | −920 663 | 10 205 210 | |
2024-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 17 240 | 92 677 | 22,85 | ||||
2023-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −943 | 75 437 | −1,23 | 100,70 | −94 960 | 7 596 506 | |
2023-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −7 631 | 76 380 | −9,08 | 99,77 | −761 345 | 7 620 433 | |
2023-02-22 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 15 855 | 84 011 | 23,26 | ||||
2022-06-14 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −19 592 | 68 156 | −22,33 | 112,71 | −2 208 214 | 7 681 863 | |
2022-06-14 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −2 882 | 87 748 | −3,18 | 112,71 | −324 830 | 9 890 077 | |
2022-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −943 | 90 630 | −1,03 | 118,15 | −111 416 | 10 707 962 | |
2022-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −5 168 | 91 573 | −5,34 | 122,41 | −632 615 | 11 209 451 | |
2022-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 80 380 | 80 380 | |||||
2022-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 17 247 | 96 741 | 21,70 | ||||
2021-06-11 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −2 881 | 79 494 | −3,50 | 109,05 | −314 173 | 8 668 821 | |
2021-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −943 | 82 375 | −1,13 | 120,61 | −113 735 | 9 935 249 | |
2021-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −2 621 | 83 318 | −3,05 | 121,58 | −318 661 | 10 129 802 | |
2021-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 71 070 | 71 070 | |||||
2021-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 13 865 | 85 939 | 19,24 | ||||
2020-06-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −872 | 72 074 | −1,20 | 90,84 | −79 216 | 6 547 490 | |
2020-06-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −2 855 | 72 946 | −3,77 | 90,27 | −257 721 | 6 584 835 | |
2020-02-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 114 940 | 114 940 | |||||
2020-02-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 18 855 | 75 801 | 33,11 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
A - Award | 48 333 | 48 333 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
D - Sale to Issuer | −48 333 | 0 | −100,00 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
A - Award | 45 500 | 45 500 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
D - Sale to Issuer | −45 500 | 0 | −100,00 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
A - Award | 196 875 | 196 875 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
D - Sale to Issuer | −196 875 | 0 | −100,00 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
A - Award | 150 000 | 150 000 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
D - Sale to Issuer | −150 000 | 0 | −100,00 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
A - Award | 19 688 | 19 688 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | −19 688 | 0 | −100,00 | ||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
A - Award | 44 625 | 44 625 | |||||
2019-07-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (Right to buy) |
D - Sale to Issuer | −44 625 | 0 | −100,00 | ||||
2019-06-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 91 367 | 91 367 | |||||
2019-06-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 39 515 | 56 946 | 226,69 | ||||
2019-06-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 17 431 | 17 431 | |||||
2019-06-12 | 3 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
0 | ||||||||
2019-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −9 500 | 140 000 | −6,35 | ||||
2019-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −9 500 | 421 983 | −2,20 | 25,59 | −243 102 | 10 798 418 |
2019-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 9 500 | 431 483 | 2,25 | 13,05 | 123 975 | 5 630 853 | |
2019-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −6 016 | 48 333 | −11,07 | ||||
2019-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −7 500 | 149 500 | −4,78 | ||||
2019-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −29 588 | 421 983 | −6,55 | 28,43 | −841 243 | 11 997 778 |
2019-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 6 016 | 451 571 | 1,35 | 1,20 | 7 219 | 541 885 | |
2019-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 7 500 | 445 555 | 1,71 | 13,05 | 97 875 | 5 814 493 | |
2019-01-18 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
A - Award | 157 500 | 157 500 | |||||
2019-01-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
A - Award | 33 800 | 438 055 | 8,36 | ||||
2019-01-03 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
F - Taxes | −10 428 | 404 255 | −2,51 | 26,57 | −277 046 | 10 740 045 | |
2018-12-26 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −35 000 | 54 349 | −39,17 | ||||
2018-12-26 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 35 000 | 414 683 | 9,22 | 1,20 | 42 000 | 497 620 | |
2018-12-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 157 000 | −3,09 | ||||
2018-12-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 379 683 | −5,00 | 29,73 | −594 504 | 11 286 153 |
2018-12-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 399 683 | 1,27 | 13,05 | 65 250 | 5 215 863 | |
2018-11-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 162 000 | −2,99 | ||||
2018-11-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 394 683 | −4,82 | 30,01 | −600 296 | 11 846 331 |
2018-11-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 414 683 | 1,22 | 13,05 | 65 250 | 5 411 613 | |
2018-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 167 000 | −2,91 | ||||
2018-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 409 683 | −4,65 | 29,63 | −592 614 | 12 139 194 |
2018-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 429 683 | 1,18 | 13,05 | 65 250 | 5 607 363 | |
2018-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 172 000 | −2,82 | ||||
2018-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 424 683 | −4,50 | 29,14 | −582 862 | 12 376 579 |
2018-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 444 683 | 1,14 | 13,05 | 65 250 | 5 803 113 | |
2018-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 177 000 | −2,75 | ||||
2018-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 439 683 | −4,35 | 26,51 | −530 194 | 11 655 864 |
2018-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 459 683 | 1,10 | 13,05 | 65 250 | 5 998 863 | |
2018-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 182 000 | −2,67 | ||||
2018-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 454 683 | −4,21 | 33,08 | −661 686 | 15 042 869 |
2018-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 474 683 | 1,06 | 13,05 | 65 250 | 6 194 613 | |
2018-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −5 000 | 187 000 | −2,60 | ||||
2018-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 469 683 | −4,08 | 36,79 | −735 710 | 17 277 524 |
2018-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 5 000 | 489 683 | 1,03 | 13,05 | 65 250 | 6 390 363 | |
2018-05-23 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 3 785 | 5 303 | 249,34 | ||||
2018-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −15 000 | 192 000 | −7,25 | ||||
2018-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −15 000 | 484 683 | −3,00 | 39,22 | −588 244 | 19 007 474 |
2018-05-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 15 000 | 499 683 | 3,09 | 13,05 | 195 750 | 6 520 863 | |
2018-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −15 000 | 207 000 | −6,76 | ||||
2018-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −15 000 | 484 683 | −3,00 | 39,59 | −593 918 | 19 190 781 |
2018-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 15 000 | 499 683 | 3,09 | 13,05 | 195 750 | 6 520 863 | |
2018-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −15 000 | 222 000 | −6,33 | ||||
2018-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −15 000 | 484 683 | −3,00 | 38,32 | −574 791 | 18 572 762 |
2018-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 15 000 | 499 683 | 3,09 | 13,05 | 195 750 | 6 520 863 | |
2018-02-16 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −15 000 | 237 000 | −5,95 | ||||
2018-02-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −15 000 | 484 683 | −3,00 | 36,40 | −545 938 | 17 640 474 |
2018-02-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 15 000 | 499 683 | 3,09 | 13,05 | 195 750 | 6 520 863 | |
2018-01-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −11 166 | 484 683 | −2,25 | 33,47 | −373 695 | 16 220 983 |
2018-01-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Options (Right to buy) |
A - Award | 119 000 | 119 000 | |||||
2018-01-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
A - Award | 25 500 | 495 849 | 5,42 | ||||
2018-01-03 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
F - Taxes | −6 834 | 470 349 | −1,43 | 33,93 | −231 897 | 15 960 259 | |
2017-12-18 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −2 000 | 6 016 | −24,95 | ||||
2017-12-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −10 685 | 477 183 | −2,19 | 31,87 | −340 512 | 15 206 963 |
2017-12-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 2 000 | 487 868 | 0,41 | 1,20 | 2 400 | 585 442 | |
2017-11-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 8 016 | −55,51 | ||||
2017-11-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 485 868 | −3,95 | 27,88 | −557 620 | 13 546 486 |
2017-11-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 505 868 | 2,02 | 1,20 | 12 000 | 607 042 | |
2017-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 18 016 | −35,69 | ||||
2017-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 495 868 | −3,88 | 28,37 | −567 336 | 14 066 188 |
2017-10-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 515 868 | 1,98 | 1,20 | 12 000 | 619 042 | |
2017-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 28 016 | −26,30 | ||||
2017-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 505 868 | −3,80 | 30,19 | −603 870 | 15 273 925 |
2017-09-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 525 868 | 1,94 | 1,20 | 12 000 | 631 042 | |
2017-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 38 016 | −20,83 | ||||
2017-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 515 868 | −3,73 | 30,79 | −615 810 | 15 883 834 |
2017-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 535 868 | 1,90 | 1,20 | 12 000 | 643 042 | |
2017-08-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
G - Gift | −35 000 | 525 868 | −6,24 | ||||
2017-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 48 016 | −17,24 | ||||
2017-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 560 868 | −3,44 | 29,03 | −580 642 | 16 283 176 |
2017-07-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 580 868 | 1,75 | 1,20 | 12 000 | 697 042 | |
2017-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −2 625 | 58 016 | −4,33 | ||||
2017-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −7 375 | 0 | −100,00 | ||||
2017-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 570 868 | −3,38 | 26,10 | −521 978 | 14 899 027 |
2017-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 7 375 | 590 868 | 1,26 | 1,20 | 8 850 | 709 042 | |
2017-06-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 2 625 | 583 493 | 0,45 | 1,20 | 3 150 | 700 192 | |
2017-05-30 |
|
4 | NVRO |
NEVRO CORP
Stock Option (Right to Buy) |
A - Award | 3 545 | 3 545 | |||||
2017-05-30 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 1 518 | 1 518 | |||||
2017-05-16 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 7 375 | −57,55 | ||||
2017-05-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 580 868 | −3,33 | 22,98 | −459 520 | 13 346 023 |
2017-05-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 600 868 | 1,69 | 1,20 | 12 000 | 721 042 | |
2017-04-18 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 17 375 | −36,53 | ||||
2017-04-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 590 868 | −3,27 | 16,06 | −321 244 | 9 490 640 |
2017-04-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 610 868 | 1,66 | 1,20 | 12 000 | 733 042 | |
2017-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −10 000 | 27 375 | −26,76 | ||||
2017-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −10 000 | 600 868 | −1,64 | 15,02 | −150 188 | 9 024 316 |
2017-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −10 000 | 610 868 | −1,61 | 15,03 | −150 265 | 9 179 208 |
2017-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 10 000 | 620 868 | 1,64 | 1,20 | 12 000 | 745 042 | |
2017-02-17 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −20 000 | 37 375 | −34,86 | ||||
2017-02-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 610 868 | −3,17 | 13,01 | −260 170 | 7 946 476 |
2017-02-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 20 000 | 630 868 | 3,27 | 1,20 | 24 000 | 757 042 | |
2017-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Options (Right to buy) |
A - Award | 252 000 | 252 000 | |||||
2017-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
A - Award | 54 000 | 610 868 | 9,70 | ||||
2016-10-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Options (Right to buy) |
M - Exercise | −400 | 56 975 | −0,70 | ||||
2016-10-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −400 | 556 868 | −0,07 | 18,00 | −7 200 | 10 023 624 |
2016-10-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 400 | 557 268 | 0,07 | 1,20 | 480 | 668 722 | |
2016-05-20 |
|
4 | NVRO |
NEVRO CORP
Stock Option (Right to Buy) |
A - Award | 3 240 | 3 240 | |||||
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −4 000 | 57 375 | −6,52 | ||||
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −8 500 | 556 868 | −1,50 | 19,50 | −165 740 | 10 858 258 |
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 4 000 | 565 368 | 0,71 | 1,20 | 4 800 | 678 442 | |
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −20 000 | 61 375 | −24,58 | ||||
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −20 000 | 561 368 | −3,44 | 18,34 | −366 848 | 10 296 836 |
2016-04-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 20 000 | 581 368 | 3,56 | 1,20 | 24 000 | 697 642 | |
2016-03-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −9 000 | 561 368 | −1,58 | 18,01 | −162 084 | 10 109 845 |
2016-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Options (Right to buy) |
A - Award | 225 000 | 225 000 | |||||
2016-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
M - Exercise | −8 000 | 81 375 | −8,95 | ||||
2016-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −12 500 | 570 368 | −2,14 | 19,26 | −240 808 | 10 987 911 |
2016-01-20 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
M - Exercise | 8 000 | 582 868 | 1,39 | 1,20 | 9 600 | 699 442 | |
2015-12-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −6 820 | 574 868 | −1,17 | 19,85 | −135 408 | 11 413 717 |
2015-11-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −6 818 | 581 688 | −1,16 | 18,00 | −122 732 | 10 471 082 |
2015-10-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −6 818 | 588 506 | −1,15 | 18,72 | −127 619 | 11 015 655 |
2015-09-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −6 818 | 595 324 | −1,13 | 25,99 | −177 229 | 15 475 031 |
2015-08-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −6 818 | 602 142 | −1,12 | 28,51 | −194 385 | 17 167 369 |
2015-07-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 608 960 | −3,07 | 29,62 | −572 153 | 18 035 934 |
2015-07-01 |
|
4 | NVRO |
NEVRO CORP
Stock Option (right to buy) |
A - Award | 5 853 | 5 853 | |||||
2015-06-16 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 628 278 | −2,98 | 29,30 | −565 992 | 18 407 729 |
2015-05-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 647 596 | −2,90 | 23,69 | −457 628 | 15 341 031 |
2015-04-17 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 666 914 | −2,82 | 25,96 | −501 544 | 17 314 755 |
2015-03-18 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 686 232 | −2,74 | 23,56 | −455 057 | 16 164 950 |
2015-02-19 |
|
4 | XENT |
Intersect ENT, Inc.
Common Stock |
S - Sale | X | −19 318 | 705 550 | −2,67 | 22,69 | −438 343 | 16 009 564 |
2015-01-23 |
|
4 | XENT |
Intersect ENT, Inc.
Stock Option (right to buy) |
A - Award | 150 000 | 150 000 | |||||
2014-07-23 | 3 | XENT |
Intersect ENT, Inc.
Common Stock |
1 475 918 | ||||||||
2014-07-23 | 3 | XENT |
Intersect ENT, Inc.
Common Stock |
777 232 | ||||||||
2014-07-23 | 3 | XENT |
Intersect ENT, Inc.
Common Stock |
1 475 918 | ||||||||
2014-07-23 | 3 | XENT |
Intersect ENT, Inc.
Common Stock |
777 232 | ||||||||
2012-06-26 |
|
4 | KNSY |
KENSEY NASH CORP
Common Stock |
D - Sale to Issuer | −5 100 | 0 | −100,00 | 38,50 | −196 350 |